Tokyo, Japan, April 02, 2016 --(PR.com
)-- Trinova Capital, an independent equity research and alternative asset management firm, has today announced that Samuel Shakeson has joined the firm as a speciality pharmaceuticals equity research analyst.
“Samuel has been in the biopharmaceutical industry for over 20 years, primarily as a clinical pharmacologist,” said Edward Barton, Senior Portfolio Manager at Trinova. “He brings a wealth of experience to Trinova Capital, having worked in the wealth management industry in the United Kingdom and USA. He is extraordinarily positioned to bring our institutional brokerage clients insight into a highly specialised sector. We all look forward to working with Sam and listening to the fresh ideas he has for the future of Trinova Capital.”
Mr Shakeson’s role will primarily be back-of-house as he will be focused on discovering new and emerging trends in the biopharmaceutical sector and he will be joining an existing team of 12.
Mr Shakeson said of his appointment, “Trinova Capital has a great presence in the Asia-Pacific region, so when the opportunity arose to work here I grasped it with both hands. I’m really excited about meeting my new team-mates and colleagues. Together we can continue to springboard Trinova Capital’s growth both in the Asia-Pacific region and worldwide for years to come.”
Mr Shakeson’s role at Trinova Capital commences Monday 4th April 2016 at the firm’s Tokyo-based headquarters.
Trinova Capital is a leading independent equity research firm based in Tokyo, Japan. Please visit www.trinovacapital.com. Alternatively, you can email email@example.com or call +813 4588 8434.